Thelansis

Osteoarthritis (OA) Market Outlook Thelansis’s “Osteoarthritis (OA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Osteoarthritis (OA) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s trajectory? What...

  Osteoarthritis (OA) is a complex condition characterized by progressive musculoskeletal pain and restricted movement, often accompanied by the deterioration of articular cartilage, changes in local bone structure, and the development of osteophytes. This joint disorder manifests differently between men and women, highlighting the importance of recognizing gender dimorphism for both prevention and treatment strategies. These structural and anatomical distinctions can be observed early and later in life, such as the thinner articular cartilage in the distal femur of girls and women compared to boys and men, leading to joint pain, capsule thickening, and osteophyte formation. Approximately 43.3% of individuals experience persistent pain, aching, or stiffness associated with osteoarthritis. The FDA has approved several drugs for the management of osteoarthritis, including Duexis (ibuprofen and famotidine), Mobic (meloxicam), Naprelan (naproxen sodium), Pennsaid (diclofenac sodium t...